 |
市場調查報告書
商品編碼
1705950
全球支氣管擴張劑市場按藥物類別、給藥途徑、適應症、分銷管道和地區分類Global Bronchodilators Market, By Drug Class, By Route of Administration, By Indication, By Distribution Channel, By Geography . |
||||||
價格
簡介目錄
2025 年全球支氣管擴張劑市場規模估計為 228.7 億美元，預計到 2032 年將達到 296.9 億美元，2025 年至 2032 年的年複合成長率（CAGR）為 3.8%。
| 報告範圍 | 報告詳細資訊 | ||
|---|---|---|---|
| 基準年 | 2024 | 2025年的市場規模 | 228.7億美元 |
| 效能數據 | 2020-2024 | 預測期 | 2025-2032 |
| 預測期：2025-2032年複合年成長率： | 3.80% | 2032年價值預測 | 296.9億美元 |
數字。 2025年全球市場佔有率（%）
支氣管擴張劑是一種可以打開肺部氣道、使呼吸更順暢的藥物。支氣管擴張劑透過放鬆和擴張支氣管周圍的平滑肌起作用，有助於緩解喘息、咳嗽、呼吸急促以及與氣喘和慢性阻塞性肺病(COPD) 等呼吸系統疾病相關的其他症狀。支氣管擴張劑有短效型和長效型，短效型用於短期緩解突發性呼吸困難，長效型則常用於控制氣喘和慢性阻塞性肺病的呼吸困難，並增強皮質類固醇對氣喘的作用。抗膽鹼藥物（也稱為抗毒蕈鹼藥物）主要用於治療 COPD，但有些也可用於治療氣喘。抗膽鹼能藥物透過阻斷膽鹼能神經來打開氣道。支氣管擴張劑的副作用因特定藥物而異。支氣管擴張劑的常見副作用包括手震、頭痛、肌肉痙攣、噁心/嘔吐和腹瀉等。
市場動態：
全球支氣管擴張劑市場的成長受到多種因素的推動，例如老齡人口增加（他們更容易患呼吸系統疾病）、都市區環境污染水平上升以及對氣喘和慢性阻塞性肺病 (COPD) 正確管理的認知不斷提高。然而，替代治療方案的可用性、長期使用支氣管擴張劑的副作用以及重磅藥物的專利到期是預計會抑制市場成長的一些主要因素。聯合治療（可同時使用兩種或兩種以上的藥物）的發展為該市場的公司創造了新的機會。此外，為了更好地控制呼吸道症狀，更加重視預防性吸入療法可能會推動未來的需求。
本研究的主要特點
- 本報告對全球支氣管擴張劑市場進行了詳細分析，並提供了預測期（2025-2032）的市場規模和年複合成長率(CAGR)，假設 2024 年為基準年。
- 它還強調了各個領域的潛在商機，並說明了該市場的有吸引力的投資提案矩陣。
- 它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景和主要企業採用的競爭策略的重要見解。
- 該報告涵蓋了全球支氣管擴張劑市場的主要企業概況，基於公司亮點、產品系列、主要產品亮點、財務表現和策略等參數。涉及的主要公司包括葛蘭素史克公司 (GSK plc.)、Astra Zeneca)、邁蘭公司 (Mylan NV)、默克公司 (Merck & Co.)、太陽製藥工業公司 (Sun Pharmaceutical Industries, Inc.)、Glenmark、諾華公司 (Novartis AG)、國際梯瓦 (Beva Industries)、國際工業製藥公司 (Boehr)、國際工業公司 (Boeva). Inc.)、西普拉 (Cipla)、Sunovion Pharmaceuticals, Inc.、賽諾菲 (Sanofi) 和 Innoviva。
- 本報告的見解將使負責人和公司經營團隊能夠就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。
- 全球支氣管擴張劑市場報告迎合了該行業的各個相關人員，例如投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
- 相關人員將透過用於分析全球支氣管擴張劑市場的各種策略矩陣更輕鬆地做出決策。
目錄
第1章 調查目的與前提條件
- 研究目標
- 先決條件
- 簡稱
第2章 市場展望
- 報告描述
- 市場定義和範圍
- 執行摘要
- Coherent Opportunity Map（COM）
第3章市場動態、法規與趨勢分析
- 市場動態
- 提高產品核可
- 嚴格的法規環境
- 加強宣傳宣傳活動
- 主要亮點
- 監管情景
- 市場趨勢
- 管道分析
- 產品發布/核准
- PEST分析
- 波特分析
- 流行病學
- 治療流程（病人歷程）
- 治療方案分析
- 主要市場參與者的新投資
- 定價分析
- 疾病意識計劃
- 分析治療的安全性和有效性
- 合併、收購和合作
4. 全球支氣管擴張劑市場-COVID-19 疫情的影響
- COVID-19流行病學
- 供需側分析
- 經濟影響
5. 2020-2032 年全球支氣管擴張劑市場（依藥物類別）
- BETA-腎上腺素能支氣管擴張劑
- 黃嘌呤衍生物
- 抗膽鹼能支氣管擴張劑
6. 全球支氣管擴張劑市場（依給藥途徑），2020-2032 年
- 口服
- 鼻腔（可吸入）
- 注射
7. 全球支氣管擴張劑市場（依適應症分類），2020 年至 2032 年
- 氣喘
- 慢性阻塞性肺病（COPD）
- 其他（慢性支氣管炎等）
8. 2020-2032 年全球支氣管擴張劑市場（依通路）
- 醫院藥房
- 零售藥局
- 網路藥局
9. 2020-2032 年全球支氣管擴張劑市場（按地區）
- 北美洲
- 歐洲
- 亞太地區
- 拉丁美洲
- 中東
- 非洲
第10章 競爭格局
- 公司簡介
- GSK plc.
- Mylan NV
- Mylan NV
- Merck &Co., Inc.
- Sun Pharmaceutical Industries Ltd.
- Glenmark Pharmaceuticals Limited
- Novartis AG
- Boehringer Ingelheim International GmbH
- Teva Pharmaceutical Industries Ltd.
- Cipla Inc.
- Sunovion Pharmaceuticals Inc.
- Sanofi
- Innoviva
第 11 章 章節
- 參考
- 調查方法
- 關於出版商
簡介目錄
Product Code: CMI6679
Global Bronchodilators Market is estimated to be valued at USD 22.87 Bn in 2025 and is expected to reach USD 29.69 Bn by 2032, growing at a compound annual growth rate (CAGR) of 3.8% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 22.87 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 3.80% | 2032 Value Projection: | USD 29.69 Bn |
Figure. Global Bronchodilators Market Share (%), By Region 2025
Bronchodilators are medications that help open up the airways in the lungs to allow for easier breathing. They work by relaxing and dilating the smooth muscles surrounding the bronchial tubes, thus reducing wheezing, coughing, shortness of breath and other symptoms associated with respiratory diseases like asthma and chronic obstructive pulmonary disease (COPD). Bronchodilators may be either short-acting used as short-term relief from sudden, unexpected attacks of breathlessness or long-acting used regularly to help control breathlessness in asthma and COPD, and increase the effectiveness of corticosteroids in asthma. Anticholinergics (also known as antimuscarinics) are mainly used to treat COPD, but a few can also be used for asthma. Anticholinergics cause the airways to widen by blocking the cholinergic nerves. The side effects of bronchodilators can vary, depending on the specific medication. General side effects of bronchodilators include trembling, particularly in the hands, headache, muscle cramps, nausea and vomiting, diarrhea, etc.
Market Dynamics:
The global bronchodilators market growth is driven by factors such as the growing geriatric population which is more susceptible to respiratory diseases, increased environmental pollution levels in both urban and rural areas, and rising awareness about proper management of asthma and COPD. However, availability of alternative treatment options, side effects associated with long term use of bronchodilators, and patent expires of blockbuster drugs are some of the key factors expected to restrain market growth. Development of combination therapies that can deliver two or more drugs simultaneously is opening new opportunities for players in this market. Moreover, greater emphasis on preventive inhalation therapies for better management of respiratory symptoms will drive future demand.
Key features of the study:
- This report provides in-depth analysis of the global bronchodilators market, and provides market size (US$ Bn) and compound annual growth rate (CAGR %) for the forecast period (2025-2032), considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global bronchodilators market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies - Key companies covered as a part of this study include GSK plc., AstraZeneca, Mylan N.V., Merck & Co., Inc., Sun Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals Limited, Novartis AG, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Cipla Inc., Sunovion Pharmaceuticals Inc., Sanofi and Innoviva
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global bronchodilators market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global bronchodilators market
Detailed Segmentation:
- Global Bronchodilators Market, By Drug Class
- Beta-adrenergic Bronchodilators
- Xanthine Derivatives
- Anticholinergic Bronchodilators
- Global Bronchodilators Market, By Route of Administration
- Oral
- Nasal (inhalable)
- Injectable
- Global Bronchodilators Market, By Indication
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
- Others (Chronic bronchitis, etc.)
- Global Bronchodilators Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Bronchodilators Market, By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
- Company Profiles
- GSK plc.
- AbbVie Inc.
- AstraZeneca
- Mylan N.V.
- Merck & Co., Inc.
- Sun Pharmaceutical Industries Ltd.
- Glenmark Pharmaceuticals Limited
- Novartis AG
- Boehringer Ingelheim International GmbH
- Teva Pharmaceutical Industries Ltd.
- Cipla Inc.
- Sunovion Pharmaceuticals Inc.
- Sanofi
- Innoviva
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Indication
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Increasing Product Approval
- Stringent Regulatory Environment
- Increasing Awareness Campaigns
- Key Highlights
- Regulatory Scenario
- Market Trends
- Pipeline Analysis
- Product Launch/Approval
- PEST Analysis
- PORTER's Analysis
- Epidemiology
- Treatment Algorithm (Patient Journey)
- Treatment Option Analysis
- New Investments by Major Market Players
- Pricing Analysis
- Disease Awareness Programs
- Treatment Safety and Efficacy Analysis
- Mergers, Acquisitions, and Collaborations
4. Global Bronchodilators Market- Impact of Coronavirus (COVID-19) Pandemic
- COVID-19 Epidemiology
- Supply Side and Demand Side Analysis
- Economic Impact
5. Global Bronchodilators Market, By Drug Class, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Beta-adrenergic Bronchodilators
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Xanthine Derivatives
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Anticholinergic Bronchodilators
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
6. Global Bronchodilators Market, By Route of Administration, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Nasal (inhalable)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
7. Global Bronchodilators Market, By Indication, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Asthma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Chronic Obstructive Pulmonary Disease (COPD)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Others (Chronic bronchitis, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
8. Global Bronchodilators Market, By Distribution Channel, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 201s9-2032, (US$ Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
9. Global Bronchodilators Market, By Region, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, By Country, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Country, 2021 -2032
- Country Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020-2032, (US$ Bn)
- North Africa
- Central Africa
- South Africa
10. Competitive Landscape
- Company Profile
- GSK plc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Mylan N.V.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Mylan N.V.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sun Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Glenmark Pharmaceuticals Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Boehringer Ingelheim International GmbH
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Cipla Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sunovion Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Innoviva
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Analyst Views
11. Section
- References
- Research Methodology
- About us
